The US research enterprise and federal investment into that enterprise is getting smaller, says the Federation of American Societies for Experimental Biology.

"Unfortunately, the research enterprise that has yielded so much in the past and that offers so much promise for the future is now under tremendous strain," FASEB says in a new report. "Research budgets have not kept pace with expanding opportunities and rising costs."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.